Treatment of brief episodes of highly symptomatic supraventricular and ventricular arrhythmias: a methodological review

Gagyi, Rita B.; Hoogendijk, Mark G.; Yap, Sing‐Chien; Szili-Török, Tamás

doi:10.1080/17434440.2021.2012449

Cited by 1 publication

(1 citation statement)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Supraventricular and ventricular arrhythmias have a high prevalence of 2.25/1000 people in all age groups, with an annual increase in incidence of 35/100,000 people [ 1 , 2 , 3 ]. Both supraventricular and ventricular arrhythmias not only cause uncomfortable symptoms such as shortness of breath, sweating, dizziness, etc., but can also be life-threatening, increasing the risk of stroke and causing or worsening heart failure, and thus they can be fatal [ 4 , 5 ]. To treat this type of disease, a number of abnormalities such as hypoxia, acidemia, electrolyte disturbances, and hyperadrenergic state need to be addressed [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Polyelectrolyte Microcapsules: An Extended Release System for the Antiarrhythmic Complex of Allapinin with Glycyrrhizic Acid Salt

Salikhov,

Musin,

Kim

et al. 2024

IJMS

View full text Add to dashboard Cite

Allapinin has antiarrhythmic activity and can be used to prevent and treat various supraventricular and ventricular arrhythmias. Nevertheless, it is highly toxic and has a number of side effects associated with non-specific accumulation in various tissues. The complex of this substance with the monoammonium salt of glycyrrhizic acid (Al:MASGA) has less toxicity and improved antiarrhythmic activity. However, the encapsulation of Al:MASGA in polyelectrolyte microcapsules (PMC) for prolonged release will reduce the residual adverse effects of this drug. In this work, the possibility of encapsulating the allapinin–MASGA complex in polyelectrolyte microcapsules based on polyallylamine and polystyrene sulfonate was investigated. The encapsulation methods of the allapinin–MASGA in polyelectrolyte microcapsules by adsorption and coprecipitation were compared. It was found that the coprecipitation method did not result in the encapsulation of Al:MASGA. The sorption method facilitated the encapsulation of up to 80% of the original substance content in solution in PMC. The release of the encapsulated substance was further investigated, and it was shown that the release of the encapsulated Al:MASGA was independent of the substance content in the capsules, but at pH 5, a two-fold decrease in the rate of drug release was observed.

show abstract